<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biochem Res Int</journal-id><journal-id journal-id-type="publisher-id">BCRI</journal-id><journal-title-group><journal-title>Biochemistry Research International</journal-title></journal-title-group><issn pub-type="ppub">2090-2247</issn><issn pub-type="epub">2090-2255</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22400116</article-id><article-id pub-id-type="pmc">3287008</article-id><article-id pub-id-type="doi">10.1155/2012/480529</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Increased Urine IgM and IgG<sub>2</sub> Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Torffvit</surname><given-names>Ole</given-names></name><xref ref-type="aff" rid="I1">
<sup>1, 2</sup>
</xref><xref ref-type="aff" rid="I2">
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Kalani</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Apelqvist</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eliasson</surname><given-names>Bj&#x000f6;rn</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Jan W.</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Brismar</surname><given-names>Kerstin</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>J&#x000f6;rneskog</surname><given-names>Gun</given-names></name><xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Nephrology, Institution of Clinical Sciences, Lund University Hospital, 22185 Lund, Sweden</aff><aff id="I2"><sup>2</sup>Primary Care Unit, Capio-Citykliniken, Bj&#x000f6;rkhemsv&#x000e4;gen 15C, 29154 Kristianstad, Sweden</aff><aff id="I3"><sup>3</sup>Department of Cardiology, Danderyd Hospital, 18288 Stockholm, Sweden</aff><aff id="I4"><sup>4</sup>Department of Endocrinology, Malm&#x000f6; University Hospital, 20502 Malm&#x000f6;, Sweden</aff><aff id="I5"><sup>5</sup>Diabetes Centrum, Sahlgrenska University Hospital, 41345 G&#x000f6;teborg, Sweden</aff><aff id="I6"><sup>6</sup>Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital, 41345 G&#x000f6;teborg, Sweden</aff><aff id="I7"><sup>7</sup>Department of Endocrinology, Karolinska University Hospital, 17164 Solna, Sweden</aff><aff id="I8"><sup>8</sup>Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 18288 Stockholm, Sweden</aff><author-notes><corresp id="cor1">*Ole Torffvit: <email>ole.torffvit@med.lu.se</email></corresp><fn fn-type="other"><p>Academic Editor: Barbara Bartolini</p></fn></author-notes><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>12</day><month>2</month><year>2012</year></pub-date><volume>2012</volume><elocation-id>480529</elocation-id><history><date date-type="received"><day>29</day><month>8</month><year>2011</year></date><date date-type="rev-recd"><day>8</day><month>11</month><year>2011</year></date><date date-type="accepted"><day>22</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Ole Torffvit et al.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Fifty-four type 2 diabetic patients with neuroischemic foot ulcers were randomised to treatment with 5000&#x02009;IU of dalteparin, (<italic>n</italic> = 28),
or physiological saline, (<italic>n</italic> = 26), once daily until ulcer healing or for a maximum of 6&#x02009;months. Thirty-three patients had normo-, 15 micro-, and 6 macroalbuminuria. The urinary levels of IgM and IgG<sub>2</sub> were elevated in 47 and 50 patients, respectively. Elevated urinary levels of IgM and IgG<sub>2</sub> indicate decreased glomerular size selectivity. Urine IgM levels were associated with IGF-1/IGFBP-1 and IGFBP-1 levels. Dalteparin treatment increased urinary levels of glycosaminoglycans (<italic>P</italic> &#x0003c; 0.001) and serum IGFBP-1 (<italic>P</italic> &#x0003c; 0.05)
while no significant effects were seen in any of the other studied parameters. In conclusion, dalteparin therapy in patients with type 2 diabetes had no effects on urinary levels of albumin, IgM, or IgG<sub>2</sub> despite significantly increased glycosaminoglycans in urine. Elevated urinary levels of IgM and IgG<sub>2</sub> might be more sensitive markers of renal disease than albuminuria in patients with type 2 diabetes and antihypertensive therapy.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Albuminuria is a marker of diabetic nephropathy and a strong predictor of widespread vascular damage [<xref rid="B1" ref-type="bibr">1</xref>]. The Steno hypothesis held that genetically based disturbances in the production or sulphation of heparan sulphate (HS) lead to a reduction of sulphated and negatively charged HS glycosaminoglycan (GAG) side chains. Negatively charged HS GAG side chains are normally found in the extracellular matrix and vascular basement membranes. High blood glucose levels lead to lower activity of the enzymes involved in GAG metabolism and sulphation of HS [<xref rid="B2" ref-type="bibr">2</xref>]. A reduction of negatively charged HS GAG may induce an increased transvascular permeability of negatively charged plasma proteins, which promotes vascular and glomerular changes [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Positive effects of heparin on diabetic nephropathy have been shown in experimental studies [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. In humans with diabetes, several studies have shown a reduction of urinary albumin excretion during treatment with unfractioned heparin, low-molecular-weight heparins (LMWH), or oral treatment with sulodexide, suggesting that these compounds can improve GAG metabolism and sulphation of HS [<xref rid="B3" ref-type="bibr">3</xref>]. Thus, in patients with type 1 diabetes, treatment with unfractionated heparin, sulodexide or LMWH decreased the albumin excretion rate [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>], whereas in type 2 diabetes, the effect on albuminuria seems less consistent [<xref rid="B3" ref-type="bibr">3</xref>]. In a study by Nielsen et al., three weeks of daily injections of the LMWH tinzaparin had no effect on albuminuria in patients with type 2 diabetes [<xref rid="B11" ref-type="bibr">11</xref>]. We have earlier reported an improved outcome of chronic neuroischemic foot ulcers in patients with diabetes during long-term treatment with dalteparin [<xref rid="B12" ref-type="bibr">12</xref>]. The beneficial effects of dalteparin on ulcer outcome involved an inhibitory effect on thrombin generation and improved haemostatic and microvascular functions [<xref rid="B13" ref-type="bibr">13</xref>]. The described effects of dalteparin may be beneficial not only for outcome of neuroischemic diabetic foot ulcers but also for other complications, such as diabetic nephropathy. Thus, the aim of this ancillary study was to investigate the effect of treatment with the LMWH dalteparin on proteinuria in patients with diabetes and severe vascular complications. The selectivity of the glomerular filter was studied by analyzing the urinary excretion of molecules of different size and charges [<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>], that is, IgM was analysed for determination of the size, and IgG<sub>2</sub> and IgG<sub>4</sub> for determination of the neutral and negative charges of the glomerular filter, respectively. The glomerular mesangial matrix turnover was assessed by measuring the urinary excretion of cytokine transforming growth factor beta 1 (TGF<italic>&#x003b2;</italic>1) [<xref rid="B18" ref-type="bibr">18</xref>]. Furthermore, we analyzed insulin-like growth factor 1 (IGF-1) and IGF-binding protein 1 (IGFBP-1) since the IGFBP-1 [<xref rid="B19" ref-type="bibr">19</xref>] and IGF1 have been shown to be associated with diabetes nephropathy independent of the degree of albumin [<xref rid="B20" ref-type="bibr">20</xref>]. It has been speculated that low IGF-1 activity may induce apoptosis or loss of podocytes and thus lead to glomerulosclerosis [<xref rid="B21" ref-type="bibr">21</xref>].</p></sec><sec id="sec2"><title>2. Subjects and Methods</title><sec sec-type="subsection" id="sec2.1"><title>2.1. Subjects</title><p>Of the previously described 87 diabetic patients [<xref rid="B12" ref-type="bibr">12</xref>] with peripheral arterial occlusive disease (PAOD) and chronic foot ulcer, 54 type 2 diabetic patients who completed the urine collections were included in the present study. All patients were treated with 75&#x02009;mg aspirin once daily since at least four weeks before randomization and throughout the study period.</p></sec><sec sec-type="subsection" id="sec2.2"><title>2.2. Methods</title><p>Prospective, double-blind, and placebo-controlled multicenter study to evaluate the effects of dalteparin (Fragmin, Pfizer) primarily on healing of neuroischemic foot ulcers [<xref rid="B12" ref-type="bibr">12</xref>] and secondarily on haemostatic and microvascular functions [<xref rid="B13" ref-type="bibr">13</xref>], and renal excretion of proteins. The patients were randomized to treatment with 0.2&#x02009;mL daily subcutaneous injections of dalteparin (25000&#x02009;U/mL) or physiological saline until ulcer healing or for a maximum of six months.</p><p>Timed urine collections from three consecutive nights before and at the end of treatment were stored at &#x02212;20&#x000b0;C and analyzed at the Renal Laboratory, Lund. Microalbuminuria was defined as a mean value of the urine collections of 20 to 200&#x02009;<italic>&#x003bc;</italic>g/min or u-albumin/creatinine ratio of 3&#x02013;30&#x02009;mg/mmol. An excretion below these levels was defined as normo- and an excretion above as macroalbuminuria.</p><p>Urine albumin [<xref rid="B22" ref-type="bibr">22</xref>], total GAG [<xref rid="B23" ref-type="bibr">23</xref>], IgM [<xref rid="B24" ref-type="bibr">24</xref>], IgG<sub>2</sub>, and IgG<sub>4</sub> [<xref rid="B25" ref-type="bibr">25</xref>] were analyzed as previously described. Biologically active TGF<italic>&#x003b2;</italic>1 was analyzed with a commercially available assay (Emax Immunoassay System, Promega Corp., Madison, WI, USA). U-creatinine was analyzed with an enzymatic method (EKTACHEM, Clinical Chemistry Slide, Johnson &#x00026; Johnson Clinical Diagnostics, Rochester, NY, USA). HbA<sub>1c</sub> was analyzed by an immunoturbidimetric method (UNIMATE 3 HbA<sub>1c</sub>, Roche Diagnostics). HsCRP and S-AA were measured using particle-enhanced immunonephelometric methods (BN, Dade Behring). IGF-I [<xref rid="B26" ref-type="bibr">26</xref>] and IGFBP-1 [<xref rid="B27" ref-type="bibr">27</xref>] were determined in serum by radioimmunoassays (RIAs).</p></sec><sec sec-type="subsection" id="sec2.3"><title>2.3. Statistical Methods</title><p>Data are shown as mean and SD and skewed variables as median (minimum and maximum values). For differences within subjects we used Friedman's test, with Wilcoxon signed-rank test as post hoc test. The chi-square test was used to compare differences in the distribution of categorical variables. For testing of differences between subject groups, the Mann-Whitney <italic>U</italic> test was used. <italic>P</italic> values below 0.05 were considered significant (2-tailed). The statistical program SPSS was used.</p></sec><sec sec-type="subsection" id="sec2.4"><title>2.4. Ethical Considerations</title><p>The study protocol was approved by the local ethics committee of each centre and the Swedish Medical Products Agency. Written informed consent was obtained from all patients.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec sec-type="subsection" id="sec3.1"><title>3.1. Patient Characteristics</title><p>Fifty-four patients with type 2 diabetes were able to leave timed urine collections from three consecutive nights before and at the end of treatment period. All patients had PAOD, peripheral neuropathy, and chronic foot ulcers. Seven patients in the dalteparin and 10 in the placebo group had suffered from myocardial infarction, and two patients in the placebo group had undergone leg amputation. Except for more ex-smokers in the placebo group, the baseline patient characteristics were not different between the two groups (<xref ref-type="table" rid="tab1">Table 1</xref>). Levels of HbA<sub>1c</sub> at baseline (<xref ref-type="table" rid="tab1">Table 1</xref>) and at the end of treatment period (dalteparin: 7.0 (4.9&#x02013;10.8)%; placebo: 6.3 (4.6&#x02013;8.7)%) were not significantly different between the groups. Ten patients in the dalteparin group and 11 in the placebo group had micro- or macroalbuminuria (<xref ref-type="table" rid="tab1">Table 1</xref>). Thirty-six patients, including 23 patients with normoalbuminuria, were on antihypertensive treatment (<xref ref-type="table" rid="tab1">Table 1</xref>).</p></sec><sec sec-type="subsection" id="sec3.2"><title>3.2. Treatment Period</title><p>The treatment period with dalteparin was not significantly different from the treatment period in the placebo group. It lasted for median 26 and range 8 to 26 weeks.</p></sec><sec sec-type="subsection" id="sec3.3"><title>3.3. Renal Parameters</title><p>At baseline, 33 patients had normo-, 15 micro-, and 6 macroalbuminuria. Thirty-six patients, including 23 patients with normoalbuminuria, were on antihypertensive treatment (<xref ref-type="table" rid="tab1">Table 1</xref>). Ten patients in the dalteparin group and 11 in the placebo group had micro- or macroalbuminuria (<xref ref-type="table" rid="tab1">Table 1</xref>). Forty-seven patients showed elevated urinary levels of IgM (<xref ref-type="fig" rid="fig1">Figure 1</xref>), while 50 patients had elevated urinary levels of IgG<sub>2</sub>, both indicating decreased glomerular size selectivity. Twelve patients had a ratio of IgG<sub>2</sub>/IgG<sub>4</sub> less than 1 indicating decreased charge selectivity, while 8 patients had urine levels of GAG less than or equal to 2&#x02009;mg/mmol.</p><p> Urinary GAG increased from 2.43 (0&#x02013;8.65) mg/mmol at baseline to 3.40 (1.25&#x02013;8.0) mg/mmol during dalteparin therapy (<italic>P</italic> &#x0003c; 0.001), while GAG levels were not significantly changed in the placebo group (baseline: 2.53 (0&#x02013;8.99) mg/mmol). All other urinary parameters, including glomerular filtration rate (GFR), were not significantly different between dalteparin- and placebo-treated patients at baseline or at the end of treatment (Tables <xref ref-type="table" rid="tab1">1</xref> and <xref ref-type="table" rid="tab2">2</xref>; data at end of treatment not shown). Baseline levels of systolic blood pressure, HbA<sub>1c</sub>, S-creatinine, S-HsCRP, S-AA, S-IGF, S-IGFBP-1, U-GAG, and U-IgG<sub>2</sub>/IgG<sub>4</sub> were not significantly different between patients with normo- and micro- or macroalbuminuria (<xref ref-type="table" rid="tab2">Table 2</xref>), and no associations were found between urinary GAG, HbA<sub>1c</sub>, and blood pressure levels and the urinary parameters. Urine levels of IgG<sub>2</sub> and IgG<sub>4</sub> were higher in patients with micro- or macroalbuminuria than in those with normoalbuminuria (<italic>P</italic> &#x0003c; 0.05) (<xref ref-type="table" rid="tab2">Table 2</xref>). The dalteparin-induced increase in urinary GAG was independent of the degree of albuminuria, and no gender differences were found (data not shown). No significant effects of dalteparin treatment were seen on the urinary excretion of proteins in either patients with normoalbuminuria, or in patients with micro- or macroalbuminuria (Tables <xref ref-type="table" rid="tab3">3</xref> and <xref ref-type="table" rid="tab4">4</xref>).</p></sec><sec sec-type="subsection" id="sec3.4"><title>3.4. Comparisons with Data from Control Subjects</title><p>In comparison with control subjects [<xref rid="B28" ref-type="bibr">28</xref>], the urinary levels of IgG<sub>2</sub> were higher in the patients with micro- or macroalbuminuria while normal in those with normoalbuminuria. Levels of IgG<sub>4</sub> were normal, while IgG<sub>2</sub>/IgG<sub>4</sub> ratios, and IgM and TGF<italic>&#x003b2;</italic>1-values [<xref rid="B18" ref-type="bibr">18</xref>] were increased irrespective of the level of albuminuria (for reference values, see <xref ref-type="table" rid="tab2">Table 2</xref>).</p></sec><sec sec-type="subsection" id="sec3.5"><title>3.5. Inflammatory Parameters, IGF-1 and IGFBP-1</title><p>The levels of hsCRP, SAA, S-IGF-1, and S-IGFBP-1 were similar in the dalteparin and placebo groups at baseline and during the treatment period (data not shown), except for S-IGFBP-1 which increased in patients with micro-macroalbuminuria in comparison with placebo-treated patients (Tables <xref ref-type="table" rid="tab3">3</xref> and <xref ref-type="table" rid="tab4">4</xref>). No associations were found with any of the urinary parameters or HbA1c levels. S-IGF-1 was negatively associated with systolic BP at entry (<italic>r</italic> = &#x02212;0.304, <italic>P</italic> = 0.048, <italic>n</italic> = 43). SAA and hsCRP were negatively associated with systolic BP at endpoint (<italic>r</italic> = &#x02212;0.294, <italic>P</italic> = 0.038, <italic>n</italic> = 50 and <italic>r</italic> = &#x02212;0.292, <italic>P</italic> = 0.036, <italic>n</italic> = 52; resp.). No differences were found between normo- and micro- or macroalbuminuric patients (<xref ref-type="table" rid="tab2">Table 2</xref>). However, urine IgM/creatinine ratio was correlated to IGF1/IGFBP1 (<italic>r</italic> = &#x02212;0.36, <italic>P</italic> = 0.008, <italic>n</italic> = 54) and IGFBP1 (<italic>r</italic> = 0.34, <italic>P</italic> = 0.013, <italic>n</italic> = 54).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The results of the present study show that six months of treatment with the LMWH dalteparin had no effect on glomerular function, inflammatory parameters, or urinary levels of proteins despite an increased urinary excretion of GAG. Our results extend the findings of an earlier study showing that three weeks of LMWH treatment had no effect on albuminuria in patients with type 2 diabetes [<xref rid="B11" ref-type="bibr">11</xref>]. These findings are in contrast to the effect seen in type 1 diabetic patients showing a reduced albuminuria during one-to-three month treatment with either unfractionated heparin or LMWH [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. The reason for this discrepancy in effects of heparins on urinary excretion of proteins between patients with type 1 and type 2 diabetes is unclear and cannot be explained by the present study. However, the structure of the heparin molecule might be of importance since mixed compositions of sulphated GAG and heparan sulphate, for example, danaparoid [<xref rid="B29" ref-type="bibr">31</xref>], seemed to be more effective in type 2 diabetic patients. Another compound sulodexide which is a mixture of glucuronyl glycos aminoglycan and dermatan sulphate in an early study seemed to be effective [<xref rid="B30" ref-type="bibr">32</xref>], while a later double-blind randomized study showed that the drug was unable to decrease urine albumin excretion in patients with type 2 diabetic nephropathy and microalbuminuria [<xref rid="B31" ref-type="bibr">33</xref>].</p><p>The levels of total urinary GAG increased during treatment with dalteparin, which may be due to restitution of glomerular GAG or simply by an increased urinary excretion of dalteparin [<xref rid="B32" ref-type="bibr">34</xref>]. The low-molecular-weight heparin dalteparin is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range 2000&#x02013;9000. An earlier study by our group showed normal excretion of GAG in normoalbuminuric type 1 diabetic patients, while the levels were decreased in micro- and macroalbuminuric patients [<xref rid="B25" ref-type="bibr">25</xref>]. In contrast, the present study showed no significant differences in the levels of GAG in patients with normal or increased urinary excretion of albumin.</p><p>Normally, the urinary levels of IgG<sub>2</sub>, IgG<sub>4</sub>, and IgM are undetectable. In the present study, more patients had increased levels of urinary IgG<sub>2,</sub> IgG<sub>2</sub>/IgG<sub>4</sub> ratio, or IgM than patients who had micro- or macroalbuminuria. The loss of negative charges of the glomerular capillary wall causes the &#x0201c;effective&#x0201d; small pore radius vis-&#x000e0;-vis negatively charged macromolecules to increase to ~4.5&#x02009;nm, which allows the passage of albumin. Larger proteins, such as IgG (mol radius 5.5&#x02009;nm) or IgM (mol radius 12&#x02009;nm), are still unable to pass across this pathway. IgG passes the glomerular capillary walls through the large pores, while IgM can permeate the glomerular capillary wall solely through the shunts [<xref rid="B28" ref-type="bibr">28</xref>]. Thus, increased transport of IgG indicates increased density of large pores, while increased concentration of urine IgM indicates increased density of shunts in the glomerular capillary wall [<xref rid="B28" ref-type="bibr">28</xref>]. In the present study, 47 patients had detectable levels of IgM, while only 21 patients had albuminuria; thus, renal disease was found in patients not detected by analysis for urine albumin. Since peripheral arterial occlusive disease is a marker of widespread vascular disease, one could expect that more patients in the present study would have had albuminuria. One reason for the low number may be antihypertensive medication, which was common in the present study. Thus, albuminuria may be a less sensitive parameter for evaluating nephropathy in patients on antihypertensive treatment. LMWH had no effect on the other urinary parameters studied, that is, IgG<sub>2</sub>/IgG<sub>4</sub>, IgG<sub>2</sub> or IgM. In recent years new technologies of genomic analysis and proteomic approaches have detected several new markers for renal disease like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocin [<xref rid="B33" ref-type="bibr">35</xref>&#x02013;<xref rid="B35" ref-type="bibr">37</xref>]. However, the substances have not been proved to be of significant prognostic value and thus the findings have not resulted in improvement of the management of diabetic nephropathy [<xref rid="B36" ref-type="bibr">38</xref>, <xref rid="B37" ref-type="bibr">39</xref>].</p><p>We have previously found higher renal excretion of IgM, IgG<sub>2</sub>, and IgG<sub>2</sub>/IgG<sub>4</sub> in type 2 than in type 1 diabetic patients with overt nephropathy despite similar degree of albuminuria [<xref rid="B28" ref-type="bibr">28</xref>]. Thus, proteinuria in type 2 diabetic patients may be caused by an alteration of the size selective properties of the glomerular capillary wall, including the occurrence of nondiscriminatory &#x0201c;shunt pathways,&#x0201d; rather than by charge selectivity [<xref rid="B15" ref-type="bibr">15</xref>]. We have previously found increased excretion of IgM to be a poor prognostic factor [<xref rid="B38" ref-type="bibr">40</xref>]. The IGFBP-1 gene has been suspected to be protective for nephropathy [<xref rid="B19" ref-type="bibr">19</xref>], possibly through altered IGFBP-1 binding to IGF-1 with local effect in the kidney. In the present study in patients with vascular disease we found increased excretion of IgM, and thus these patients may be at increased risk. We furthermore found a positive association between IGFBP-1 and excretion of IgM indicating that high IGFBP-1 may be associated with glomerular damage. Thus, we were able to confirm decreased levels of IGF-1 and increased levels of IGFBP-1 in type 2 diabetes patients with nephropathy [<xref rid="B20" ref-type="bibr">20</xref>]. Furthermore, IGFBP-1 increased to significantly higher levels in patients treated with dalteparin than in placebo-treated ones. The reason for these increased levels is not known but may be due to reduced proteolysis of IGFBP-1. In line with a study by Sharma et al. [<xref rid="B18" ref-type="bibr">18</xref>], the present study showed increased urinary levels of TGF<italic>&#x003b2;</italic>1 in patients with type 2 diabetes. However, the levels of TGF<italic>&#x003b2;</italic>1 were also unaffected by dalteparin treatment.</p><p>In conclusion, the present study showed no effects of dalteparin on the glomerular filter despite increased S-IGFBP-1 levels and urinary levels of GAG. Thus, the study indicates that proteinuria in type 2 diabetic patients may be caused by an alteration of the size-selective properties of the glomerular capillary wall. IgM and IgG<sub>2</sub> seem to be better markers than albuminuria for severe vascular disease.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Ann-Christin Salomonsson, Microcirculation Laboratory, Karolinska Institute, Department of Clinical Sciences, Danderyd Hospital, Stockholm, and &#x000c5;sa Pettersson, Renal Laboratory, Lund University Hospital, for skilful assistance and Inga-Lena Wivall (Department of Molecular Medicine and Surgery, Karolinska Institute) for help with the analyses of IGF-1 and IGFBP-1. Grants were received from the Pharmacia Corporation, the Swedish Heart-Lung Foundation, the Stockholm County Council, and the R&#x00026;D Department of the Public Health and Medical Services Committee and the Swedish Research Council (VR 04224). This study was supported by an unrestricted grant from Pharmacia Corporation, who also supplied the dalteparin and placebo injections. Pharmacia Corporation had no input into the study design, its execution, or interpretation of the findings.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>IgG:</term><def><p>Immunoglobulin G</p></def></def-item><def-item><term>TGF<italic>&#x003b2;</italic>1:</term><def><p>Transforming growth factor <italic>&#x003b2;</italic>1</p></def></def-item><def-item><term>IGF-1:</term><def><p>Insulin-like growth factor 1</p></def></def-item><def-item><term>IGFBP-1:</term><def><p>Insulin-like growth factor binding protein 1.</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deckert</surname><given-names>T</given-names></name><name><surname>Feldt-Rasmussen</surname><given-names>B</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Jensen</surname><given-names>T</given-names></name><name><surname>Kofoed-Enevoldsen</surname><given-names>A</given-names></name></person-group><article-title>Albuminuria reflects widespread vascular damage. The steno hypothesis</article-title><source><italic>Diabetologia</italic></source><year>1989</year><volume>32</volume><issue>4</issue><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">2668076</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kofoed-Enevoldsen</surname><given-names>A</given-names></name><name><surname>Noonan</surname><given-names>D</given-names></name><name><surname>Deckert</surname><given-names>T</given-names></name></person-group><article-title>Diabetes mellitus induced inhibition of glucosaminyl N-deacetylase: effect of short-term blood glucose control in diabetic rats</article-title><source><italic>Diabetologia</italic></source><year>1993</year><volume>36</volume><issue>4</issue><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">8477875</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambaro</surname><given-names>G</given-names></name><name><surname>Van Der Woude</surname><given-names>FJ</given-names></name></person-group><article-title>Glycosaminoglycans: use in treatment of diabetic nephropathy</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2000</year><volume>11</volume><fpage>359</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">10665944</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamsma</surname><given-names>JT</given-names></name><name><surname>Van Den Born</surname><given-names>J</given-names></name><name><surname>Bruijn</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane</article-title><source><italic>Diabetologia</italic></source><year>1994</year><volume>37</volume><issue>3</issue><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">8174847</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>NP</given-names></name><name><surname>Shires</surname><given-names>M</given-names></name><name><surname>Crellin</surname><given-names>DM</given-names></name><name><surname>Aparicio</surname><given-names>SR</given-names></name><name><surname>Davison</surname><given-names>AM</given-names></name></person-group><article-title>Alterations of glomerular basement membrane charge and structure in diabetic nephropathy</article-title><source><italic>Diabetologia</italic></source><year>1995</year><volume>38</volume><issue>12</issue><fpage>1455</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">8786020</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oturai</surname><given-names>PS</given-names></name><name><surname>Rasch</surname><given-names>R</given-names></name><name><surname>Hasselager</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats</article-title><source><italic>Acta Pathologica, Microbiologica et Immunologica Scandinavica</italic></source><year>1996</year><volume>104</volume><issue>4</issue><fpage>259</fpage><lpage>264</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>SM</given-names></name><name><surname>Hansen</surname><given-names>KW</given-names></name><name><surname>&#x000d8;sterby</surname><given-names>R</given-names></name><name><surname>Frystyk</surname><given-names>J</given-names></name><name><surname>&#x000d8;rskov</surname><given-names>H</given-names></name><name><surname>Flyvbjerg</surname><given-names>A</given-names></name></person-group><article-title>Effects of heparin on renal morphology and albuminuria in experimental diabetes</article-title><source><italic>American Journal of Physiology</italic></source><year>1996</year><volume>271</volume><issue>2</issue><fpage>E326</fpage><lpage>E332</lpage><pub-id pub-id-type="pmid">8770027</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichikawa</surname><given-names>I</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Fogo</surname><given-names>A</given-names></name><name><surname>Purkerson</surname><given-names>ML</given-names></name><name><surname>Klahr</surname><given-names>S</given-names></name></person-group><article-title>Effect of heparin on the glomerular structure and function of remnant nephrons</article-title><source><italic>Kidney International</italic></source><year>1988</year><volume>34</volume><issue>5</issue><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">3199677</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myrup</surname><given-names>B</given-names></name><name><surname>Hansen</surname><given-names>PM</given-names></name><name><surname>Jensen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus</article-title><source><italic>The Lancet</italic></source><year>1995</year><volume>345</volume><issue>8947</issue><fpage>421</fpage><lpage>422</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamsma</surname><given-names>JT</given-names></name><name><surname>Van Der Woude</surname><given-names>FJ</given-names></name><name><surname>Lemkes</surname><given-names>HHPJ</given-names></name></person-group><article-title>Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy</article-title><source><italic>Nephrology Dialysis Transplantation</italic></source><year>1996</year><volume>11</volume><issue>1</issue><fpage>182</fpage><lpage>185</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Schmitz</surname><given-names>A</given-names></name><name><surname>Bacher</surname><given-names>T</given-names></name><name><surname>Rehling</surname><given-names>M</given-names></name><name><surname>Ingerslev</surname><given-names>J</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name></person-group><article-title>Transcapillary escape rate and albuminuria in type II diabetes. Effects of short-term treatment with low-molecular weight heparin</article-title><source><italic>Diabetologia</italic></source><year>1999</year><volume>42</volume><issue>1</issue><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">10027580</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalani</surname><given-names>M</given-names></name><name><surname>Apelqvist</surname><given-names>J</given-names></name><name><surname>Blomb&#x000e4;ck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of dalteparin on healing of chronic fott ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomised, double-blind and placebo-controlled study</article-title><source><italic>Diabetes Care</italic></source><year>2003</year><volume>26</volume><issue>9</issue><fpage>2575</fpage><lpage>2580</lpage><pub-id pub-id-type="pmid">12941721</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalani</surname><given-names>M</given-names></name><name><surname>Silveira</surname><given-names>A</given-names></name><name><surname>Apelqvist</surname><given-names>J</given-names></name><etal/></person-group><article-title>Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers</article-title><source><italic>Thrombosis Research</italic></source><year>2007</year><volume>120</volume><issue>5</issue><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">17275886</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>Y</given-names></name><name><surname>Tani</surname><given-names>N</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Shibata</surname><given-names>A</given-names></name></person-group><article-title>Glomerular charge selectivity in non-insulin-dependent diabetes mellitus</article-title><source><italic>Journal of Diabetes and Its Complications</italic></source><year>1991</year><volume>5</volume><issue>2-3</issue><fpage>135</fpage><lpage>137</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morano</surname><given-names>S</given-names></name><name><surname>Pietravalle</surname><given-names>P</given-names></name><name><surname>De Rossi</surname><given-names>MG</given-names></name><etal/></person-group><article-title>A charge selectivity impairment in protein permselectivity is present in type 2 diabetes</article-title><source><italic>Acta Diabetologica</italic></source><year>1993</year><volume>30</volume><issue>3</issue><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">8111073</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gall</surname><given-names>MA</given-names></name><name><surname>Kofoed-Enevoldsen</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>FS</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name></person-group><article-title>Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy</article-title><source><italic>Diabetologia</italic></source><year>1994</year><volume>37</volume><issue>2</issue><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">8163055</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Imanishi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients</article-title><source><italic>Diabetes Care</italic></source><year>1998</year><volume>21</volume><issue>4</issue><fpage>482</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">9571328</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Ziayadeh</surname><given-names>F</given-names></name><name><surname>Alzahabi</surname><given-names>B</given-names></name><etal/></person-group><article-title>Increased renal production of transforming growth factor-<italic>&#x003b2;</italic>1 in patients with type II diabetes</article-title><source><italic>Diabetes/Metabolism Reviews</italic></source><year>1997</year><volume>46</volume><issue>5</issue><fpage>854</fpage><lpage>859</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>R</given-names></name><name><surname>McElduff</surname><given-names>P</given-names></name><name><surname>Heald</surname><given-names>A</given-names></name><etal/></person-group><article-title>Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes</article-title><source><italic>Diabetes/Metabolism Reviews</italic></source><year>2005</year><volume>54</volume><issue>12</issue><fpage>3547</fpage><lpage>3553</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akturk</surname><given-names>M</given-names></name><name><surname>Arslan</surname><given-names>M</given-names></name><name><surname>Altinova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus</article-title><source><italic>Growth Hormone &#x00026; IGF Research</italic></source><year>2007</year><volume>17</volume><issue>3</issue><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">17329141</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasylyeva</surname><given-names>T</given-names></name><name><surname>Ferry</surname><given-names>RJ</given-names><suffix>Jr.</suffix></name></person-group><article-title>Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy</article-title><source><italic>Diabetes Research and Clinical Practice</italic></source><year>2007</year><volume>76</volume><issue>2</issue><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">17011663</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torffvit</surname><given-names>O</given-names></name><name><surname>Wieslander</surname><given-names>J</given-names></name></person-group><article-title>A simplified enzyme-linked immunosorbent assay for urinary albumin</article-title><source><italic>Scandinavian Journal of Clinical &#x00026; Laboratory Investigation</italic></source><year>1986</year><volume>46</volume><issue>6</issue><fpage>545</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">3775240</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tencer</surname><given-names>J</given-names></name><name><surname>Torffvit</surname><given-names>O</given-names></name><name><surname>Grubb</surname><given-names>A</given-names></name><name><surname>Bj&#x000f6;rnsson</surname><given-names>S</given-names></name><name><surname>Thysell</surname><given-names>H</given-names></name><name><surname>Rippe</surname><given-names>B</given-names></name></person-group><article-title>Decreased excretion of urine glycosaminoglycans as marker in renal amyloidosis</article-title><source><italic>Nephrology Dialysis Transplantation</italic></source><year>1997</year><volume>12</volume><issue>6</issue><fpage>1161</fpage><lpage>1166</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tencer</surname><given-names>J</given-names></name><name><surname>Torffvit</surname><given-names>O</given-names></name><name><surname>Thysell</surname><given-names>H</given-names></name><name><surname>Rippe</surname><given-names>B</given-names></name><name><surname>Grubb</surname><given-names>A</given-names></name></person-group><article-title>Proteinuria selectivity index based upon <italic>&#x003b1;</italic>
<sub>2</sub>-macroglobulin or IgM is superior to the IgG based index in differentiating glomerular diseases</article-title><source><italic>Kidney International</italic></source><year>1998</year><volume>54</volume><issue>6</issue><fpage>2098</fpage><lpage>2105</lpage><pub-id pub-id-type="pmid">9853275</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torffvit</surname><given-names>O</given-names></name><name><surname>Rippe</surname><given-names>B</given-names></name></person-group><article-title>Size and charge selectivity of the glomerular filter in patients with insulin-dependent diabetes mellitus: urinary immunoglobulins and glycosaminoglycans</article-title><source><italic>Nephron</italic></source><year>1999</year><volume>83</volume><issue>4</issue><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">10575291</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>U</given-names></name><name><surname>Sara</surname><given-names>V</given-names></name><name><surname>Wivall</surname><given-names>I</given-names></name><name><surname>Hall</surname><given-names>K</given-names></name></person-group><article-title>Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand</article-title><source><italic>Acta Endocrinologica (Copenhagen)</italic></source><year>1991</year><volume>124</volume><issue>6</issue><fpage>620</fpage><lpage>629</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000f3;va</surname><given-names>G</given-names></name><name><surname>Roovete</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>K</given-names></name></person-group><article-title>Crossreaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin binding protein isolated from human amniotic fluid</article-title><source><italic>Acta Endocrinologica (Copenhagen)</italic></source><year>1984</year><volume>107</volume><issue>4</issue><fpage>563</fpage><lpage>570</lpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakoush</surname><given-names>O</given-names></name><name><surname>Tencer</surname><given-names>J</given-names></name><name><surname>Tapia</surname><given-names>J</given-names></name><name><surname>Rippe</surname><given-names>B</given-names></name><name><surname>Torffvit</surname><given-names>O</given-names></name></person-group><article-title>Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy</article-title><source><italic>Kidney International</italic></source><year>2002</year><volume>61</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">11786102</pub-id></element-citation></ref><ref id="B39"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Und&#x000e9;n</surname><given-names>A-L</given-names></name><name><surname>Elofsson</surname><given-names>S</given-names></name><name><surname>Brismar</surname><given-names>K</given-names></name></person-group><article-title>Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study</article-title><source><italic>Clinical Endocrinology</italic></source><year>2005</year><volume>63</volume><issue>1</issue><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">15963068</pub-id></element-citation></ref><ref id="B40"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Und&#x000e9;n</surname><given-names>A-L</given-names></name><name><surname>Elofsson</surname><given-names>S</given-names></name><name><surname>Knox</surname><given-names>S</given-names></name><name><surname>Lewitt</surname><given-names>M</given-names></name><name><surname>Brismar</surname><given-names>K</given-names></name></person-group><article-title>IGF-I in a normal population: relation to psychosocial factors</article-title><source><italic>Clinical Endocrinology</italic></source><year>2002</year><volume>57</volume><issue>6</issue><fpage>793</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">12460330</pub-id></element-citation></ref><ref id="B29"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Pijl</surname><given-names>J</given-names></name><name><surname>van der Woude</surname><given-names>F</given-names></name><name><surname>Geelhoed-Duijvestijn</surname><given-names>P</given-names></name><etal/></person-group><article-title>Danaparoid sodium lowers proteinuria in diabetic nephropathy</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>1997</year><volume>8</volume><issue>3</issue><fpage>456</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">9071714</pub-id></element-citation></ref><ref id="B30"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambaro</surname><given-names>G</given-names></name><name><surname>Kinalska</surname><given-names>I</given-names></name><name><surname>Oksa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2002</year><volume>13</volume><issue>6</issue><fpage>1615</fpage><lpage>1625</lpage><pub-id pub-id-type="pmid">12039991</pub-id></element-citation></ref><ref id="B31"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>E</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><etal/></person-group><article-title>Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial</article-title><source><italic>American Journal of Kidney Diseases</italic></source><year>2011</year><volume>58</volume><issue>5</issue><fpage>729</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">21872376</pub-id></element-citation></ref><ref id="B32"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawes</surname><given-names>J</given-names></name><name><surname>Prowse</surname><given-names>C</given-names></name><name><surname>Pepper</surname><given-names>DS</given-names></name></person-group><article-title>Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay</article-title><source><italic>Thrombosis Research</italic></source><year>1986</year><volume>44</volume><issue>5</issue><fpage>683</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">2433788</pub-id></element-citation></ref><ref id="B33"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>K</given-names></name><name><surname>Phadke</surname><given-names>G</given-names></name><name><surname>Nivastala</surname><given-names>R</given-names></name><name><surname>Weidmeyer</surname><given-names>C</given-names></name><name><surname>McFarlane</surname><given-names>S</given-names></name><name><surname>Whaley-Connell</surname><given-names>A</given-names></name></person-group><article-title>The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease</article-title><source><italic>Current Diabetes Reports</italic></source><year>2010</year><volume>10</volume><issue>1</issue><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20425065</pub-id></element-citation></ref><ref id="B34"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauta</surname><given-names>F</given-names></name><name><surname>van Oeveren</surname><given-names>W</given-names></name><name><surname>Boertien</surname><given-names>W</given-names></name><etal/></person-group><article-title>Glomerular and tubular damage markers are elevated in patients with diabetes</article-title><source><italic>Diabetes Care</italic></source><year>2011</year><volume>34</volume><issue>4</issue><fpage>975</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">21307379</pub-id></element-citation></ref><ref id="B35"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>W-J</given-names></name><name><surname>Xiong</surname><given-names>S-L</given-names></name><name><surname>Fang</surname><given-names>Y-G</given-names></name><etal/></person-group><article-title>Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study</article-title><source><italic>Endocrine Journal</italic></source><year>2012</year><volume>41</volume><issue>1</issue><fpage>82</fpage><lpage>88</lpage></element-citation></ref><ref id="B36"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramonti</surname><given-names>G</given-names></name><name><surname>Kanwar</surname><given-names>YS</given-names></name></person-group><article-title>Tubular biomarkers to assess progression of diabetic nephropathy</article-title><source><italic>Kidney International</italic></source><year>2011</year><volume>79</volume><issue>10</issue><fpage>1042</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">21527942</pub-id></element-citation></ref><ref id="B37"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Andersen</surname><given-names>S</given-names></name><name><surname>Zdunek</surname><given-names>D</given-names></name><name><surname>Hess</surname><given-names>G</given-names></name><name><surname>Parving</surname><given-names>H-H</given-names></name><name><surname>Rossing</surname><given-names>P</given-names></name></person-group><article-title>Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy</article-title><source><italic>Kidney International</italic></source><year>2011</year><volume>79</volume><issue>10</issue><fpage>1113</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">21270761</pub-id></element-citation></ref><ref id="B38"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakoush</surname><given-names>O</given-names></name><name><surname>Torffvit</surname><given-names>O</given-names></name><name><surname>Rippe</surname><given-names>B</given-names></name><name><surname>Tencer</surname><given-names>J</given-names></name></person-group><article-title>High proteinuria selectivity index based upon IgM is a strong predictor of poor renal survival in glomerular diseases</article-title><source><italic>Nephrology Dialysis Transplantation</italic></source><year>2001</year><volume>16</volume><issue>7</issue><fpage>1357</fpage><lpage>1363</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Box-plot of levels of IgM in control subjects compared with patients with normo- and micro- or macroalbuminuria at baseline (<italic>P</italic> &#x0003c; 0.001). Normo- versus micro- or macroalbuminuria (<italic>P</italic> = 0.05).</p></caption><graphic xlink:href="BCRI2012-480529.001"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of 54 patients randomized to dalteparin or placebo. </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">
</th><th align="center" rowspan="1" colspan="1"> All</th><th align="center" rowspan="1" colspan="1"> Dalteparin</th><th align="center" rowspan="1" colspan="1"> Placebo</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>N</italic> = 54</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic> = 28</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic> = 26</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">75 (54&#x02013;90)</td><td align="center" rowspan="1" colspan="1">73 (57&#x02013;86)</td><td align="center" rowspan="1" colspan="1">75 (54&#x02013;90)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" rowspan="1" colspan="1">37/17</td><td align="center" rowspan="1" colspan="1">17/11</td><td align="center" rowspan="1" colspan="1">20/6</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker/ex-smoker/nonsmoker (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">9/14/31</td><td align="center" rowspan="1" colspan="1">4/3/21*</td><td align="center" rowspan="1" colspan="1">5/11/10</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">6.7 (5.0&#x02013;11.0)</td><td align="center" rowspan="1" colspan="1">6.9 (5.1&#x02013;11)</td><td align="center" rowspan="1" colspan="1">6.9 (5.0&#x02013;9.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes duration (years)</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 9</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 8</td></tr><tr><td align="left" rowspan="1" colspan="1">Tablets/insulin/tablets + insulin/diet (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">10/31/8/5</td><td align="center" rowspan="1" colspan="1">4/18/3/3</td><td align="center" rowspan="1" colspan="1">6/13/5/2</td></tr><tr><td align="left" rowspan="1" colspan="1">Antihypertensive treatment (<italic>n</italic>) (ACE/<italic>&#x003b2;</italic>/Ca/diuretic/other)</td><td align="center" rowspan="1" colspan="1">10/13/5/22/4</td><td align="center" rowspan="1" colspan="1">5/6/3/14/0</td><td align="center" rowspan="1" colspan="1">5/7/2/8/4</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">158 &#x000b1; 22</td><td align="center" rowspan="1" colspan="1">160 &#x000b1; 22</td><td align="center" rowspan="1" colspan="1">155 &#x000b1; 22</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">80 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">78 &#x000b1; 9</td><td align="center" rowspan="1" colspan="1">82 &#x000b1; 12</td></tr><tr><td align="left" rowspan="1" colspan="1">P-Creatinine (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">83 (53&#x02013;160)</td><td align="center" rowspan="1" colspan="1">83 (57&#x02013;130)</td><td align="center" rowspan="1" colspan="1">84 (53&#x02013;160)</td></tr><tr><td align="left" rowspan="1" colspan="1">GFR (mL/min)</td><td align="center" rowspan="1" colspan="1">74 (17&#x02013;218)</td><td align="center" rowspan="1" colspan="1">74 (34&#x02013;190) <break/> (<italic>n</italic> = 22)</td><td align="center" rowspan="1" colspan="1">80 (17&#x02013;218) <break/>(<italic>n</italic> = 22)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Albuminuria (normo/micro/macro): </italic>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">33/15/6</td><td align="center" rowspan="1" colspan="1">18/8/2</td><td align="center" rowspan="1" colspan="1">15/7/4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;At endpoint (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">35/12/7</td><td align="center" rowspan="1" colspan="1">18/7/3</td><td align="center" rowspan="1" colspan="1">17/5/4</td></tr></tbody></table><table-wrap-foot><fn><p>*<italic>P</italic> &#x0003c; 0.05 versus placebo. Data are given as mean &#x000b1; SD, or as median and minimum-maximum values. GFR: glomerular filtration rate: creatinine clearance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Baseline values in patients grouped with normo- or micro- and macroalbuminuria. </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Normoalbuminuria</th><th align="center" rowspan="1" colspan="1">Micro- and macroalbuminuria</th></tr><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic> = 33</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic> = 21</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">74 (54&#x02013;90)</td><td align="center" rowspan="1" colspan="1">75 (61&#x02013;86)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes duration (years)</td><td align="center" rowspan="1" colspan="1">15 &#x000b1; 9</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 8</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" rowspan="1" colspan="1">21/12</td><td align="center" rowspan="1" colspan="1">16/5</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">150 (115&#x02013;210)</td><td align="center" rowspan="1" colspan="1">160 (135&#x02013;215)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">80 (60&#x02013;100)</td><td align="center" rowspan="1" colspan="1">85 (60&#x02013;105)</td></tr><tr><td align="left" rowspan="1" colspan="1">S-HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">6.5 (5.0&#x02013;9.9)</td><td align="center" rowspan="1" colspan="1">6.9 (5.1&#x02013;11.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">S-Creatinine (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">81 (53&#x02013;160)</td><td align="center" rowspan="1" colspan="1">85 (65&#x02013;128)</td></tr><tr><td align="left" rowspan="1" colspan="1">S-Hs CRP (mg/L)</td><td align="center" rowspan="1" colspan="1">9.4 (0.9&#x02013;118)</td><td align="center" rowspan="1" colspan="1">2.7 (0.3&#x02013;78.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">S-AA (mg/L)</td><td align="center" rowspan="1" colspan="1">5.5 (1.2&#x02013;415)</td><td align="center" rowspan="1" colspan="1">5.1 (1.7&#x02013;127)</td></tr><tr><td align="left" rowspan="1" colspan="1">S-IGF-1 (<italic>&#x003bc;</italic>g/L)</td><td align="center" rowspan="1" colspan="1">134 (47&#x02013;384)</td><td align="center" rowspan="1" colspan="1">115 (49&#x02013;269)</td></tr><tr><td align="left" rowspan="1" colspan="1">S-IGFBP-1 (<italic>&#x003bc;</italic>g/L)</td><td align="center" rowspan="1" colspan="1">41 (15&#x02013;310)</td><td align="center" rowspan="1" colspan="1">60 (8&#x02013;313)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-Glycosaminoglycan (mg/mmol)<sup>a</sup>
</td><td align="center" rowspan="1" colspan="1">2.7 (0&#x02013;8.7)</td><td align="center" rowspan="1" colspan="1">2.6 (0&#x02013;11.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>2</sub> (mg/mmol)<sup>b</sup>
</td><td align="center" rowspan="1" colspan="1">0.18 (0&#x02013;8.1)</td><td align="center" rowspan="1" colspan="1">0.85 (0&#x02013;99)*</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>4</sub> (mg/mmol)<sup>c</sup>
</td><td align="center" rowspan="1" colspan="1">0.06 (0&#x02013;7.7)</td><td align="center" rowspan="1" colspan="1">0.27 (0&#x02013;28.7)*</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>2</sub>/IgG<sub>4</sub>
<sup>d</sup>
</td><td align="center" rowspan="1" colspan="1">3.1 (0.04&#x02013;31.0)</td><td align="center" rowspan="1" colspan="1">3.3 (0.76&#x02013;10.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgM (mg/mmol)<sup>e</sup>
</td><td align="center" rowspan="1" colspan="1">0.02 (0&#x02013;0.06)</td><td align="center" rowspan="1" colspan="1">0.03 (0&#x02013;0.13)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-TGF<italic>&#x003b2;</italic>1 (ng/mmol)</td><td align="center" rowspan="1" colspan="1">3.2 (1.1&#x02013;379)</td><td align="center" rowspan="1" colspan="1">4.5 (1.4&#x02013;16.5)</td></tr></tbody></table><table-wrap-foot><fn><p>*<italic>P</italic> &#x0003c; 0.05 versus normoalbuminuria. Data are given as median and range (min-max). Urine data are the ratio between urine protein and urine creatinine. <sup>a</sup>Reference values for U-GAG: 2.9 (2.0&#x02013;4.4) mg/mmol [<xref rid="B25" ref-type="bibr">25</xref>]; <sup>b</sup>U-IgG<sub>2</sub>: 0.19 &#x000b1; 0.14&#x02009;mg/mmol; <sup>c</sup>U-IgG<sub>4</sub>: 0.35 &#x000b1; 0.25&#x02009;mg/mmol; <sup>d</sup>U-IgG<sub>2</sub>/IgG<sub>4</sub>: 2.3 &#x000b1; 0.7; <sup>e</sup>U-IgM: 0.002 &#x000b1; 0.001&#x02009;mg/mmol [<xref rid="B28" ref-type="bibr">28</xref>]. IGFBP-1 (15&#x02013;45) [<xref rid="B39" ref-type="bibr">29</xref>, <xref rid="B40" ref-type="bibr">30</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Diabetic patients with normoalbuminuria: effects of treatment on urinary indices. </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">
</th><th align="center" colspan="2" rowspan="1">Dalteparin</th><th align="center" colspan="2" rowspan="1">Placebo</th></tr><tr><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">At endpoint</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">At endpoint</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 18</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 18</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 15</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 15</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> U-Albumin (mg/mmol)</td><td align="center" rowspan="1" colspan="1"> 0.81 (0.07&#x02013;2.39)</td><td align="center" rowspan="1" colspan="1"> 0.77 (0.06&#x02013;4.97)</td><td align="center" rowspan="1" colspan="1"> 0.81 (0.13&#x02013;4.09)</td><td align="center" rowspan="1" colspan="1"> 0.80 (0.19&#x02013;6.73)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>2</sub> (mg/mmol)</td><td align="center" rowspan="1" colspan="1">0.19 (0&#x02013;8.14)</td><td align="center" rowspan="1" colspan="1">0.14 (0&#x02013;7.79)</td><td align="center" rowspan="1" colspan="1">0.18 (0.06&#x02013;2.64)</td><td align="center" rowspan="1" colspan="1">0.16 (0.01&#x02013;3.79)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>4</sub> (mg/mmol)</td><td align="center" rowspan="1" colspan="1">0.05 (0&#x02013;7.68)</td><td align="center" rowspan="1" colspan="1">0.04 (0&#x02013;1.08)</td><td align="center" rowspan="1" colspan="1">0.07 (0.02&#x02013;2.51)</td><td align="center" rowspan="1" colspan="1">0.06 (0.02&#x02013;4.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>2</sub>/u-IgG<sub>4</sub>
</td><td align="center" rowspan="1" colspan="1">3.49 (0.04&#x02013;31)</td><td align="center" rowspan="1" colspan="1">2.20 (0.37&#x02013;44.59)</td><td align="center" rowspan="1" colspan="1">2.38 (0.41&#x02013;8.58)</td><td align="center" rowspan="1" colspan="1">2.63 (0.54&#x02013;18.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-GAG (mg/mmol)</td><td align="center" rowspan="1" colspan="1">2.43 (0.86&#x02013;8.65)</td><td align="center" rowspan="1" colspan="1">2.85 (1.32&#x02013;8)<sup>&#x02217;#</sup>
</td><td align="center" rowspan="1" colspan="1">3.32 (0&#x02013;6.45)</td><td align="center" rowspan="1" colspan="1">2.53 (0.93&#x02013;8.99)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgM (mg/mmol)</td><td align="center" rowspan="1" colspan="1">0.02 (0&#x02013;0.06)</td><td align="center" rowspan="1" colspan="1">0.02 (0&#x02013;0.05)</td><td align="center" rowspan="1" colspan="1">0.02 (0&#x02013;0.05)</td><td align="center" rowspan="1" colspan="1">0.02 (0&#x02013;0.05)</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-<italic>&#x003b2;</italic>1 (mg/mmol)</td><td align="center" rowspan="1" colspan="1">3.2 (1.1&#x02013;379)</td><td align="center" rowspan="1" colspan="1">5.17 (1.47&#x02013;21.3)</td><td align="center" rowspan="1" colspan="1">3.4 (1.4&#x02013;24.6)</td><td align="center" rowspan="1" colspan="1">3.32 (1.7&#x02013;28.9)</td></tr><tr><td align="left" rowspan="2" colspan="1">GFR (mL/min)</td><td align="center" rowspan="1" colspan="1">70 (34&#x02013;190)</td><td align="center" rowspan="1" colspan="1">65 (33&#x02013;163)</td><td align="center" rowspan="1" colspan="1">99 (17&#x02013;218)</td><td align="center" rowspan="1" colspan="1">86 (20&#x02013;334)</td></tr><tr><td align="center" rowspan="1" colspan="1">(<italic>n</italic> = 14)</td><td align="center" rowspan="1" colspan="1">(<italic>n</italic> = 13)</td><td align="center" rowspan="1" colspan="1">(<italic>n</italic> = 12)</td><td align="center" rowspan="1" colspan="1">(<italic>n</italic> = 12)</td></tr><tr><td align="left" rowspan="1" colspan="1">IGFBP-1 (<italic>&#x003bc;</italic>g/L)</td><td align="center" rowspan="1" colspan="1">42 (21&#x02013;310)</td><td align="center" rowspan="1" colspan="1">49 (27&#x02013;315)</td><td align="center" rowspan="1" colspan="1">38 (15&#x02013;98)</td><td align="center" rowspan="1" colspan="1">53 (15&#x02013;97)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are given as the median (with minimum and maximum values in parentheses) of the ratio between urinary concentrations of substance and u-creatinine. *<italic>P</italic> &#x0003c; 0.05 versus placebo; <sup>#</sup>
<italic>P</italic> &#x0003c; 0.05 versus baseline. GFR: glomerular filtration rate: creatinine clearance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Diabetic patients with micro- or macroalbuminuria: effects of treatment on urinary indices. </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">
</th><th align="center" colspan="2" rowspan="1">Dalteparin</th><th align="center" colspan="2" rowspan="1">Placebo</th></tr><tr><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">At end point</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">At end point</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 10</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 10</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 11</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 11</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> U-Albumin (mg/mmol)</td><td align="center" rowspan="1" colspan="1"> 8.5 (0.9&#x02013;435)</td><td align="center" rowspan="1" colspan="1"> 11.3 (1.5&#x02013;311)</td><td align="center" rowspan="1" colspan="1"> 23.2 (2.1&#x02013;187)</td><td align="center" rowspan="1" colspan="1"> 7.9 (0.9&#x02013;273) <break/> (<italic>n</italic> = 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>2</sub> (mg/mmol)</td><td align="center" rowspan="1" colspan="1">0.46 (0&#x02013;20.7)</td><td align="center" rowspan="1" colspan="1">0.83 (0.13&#x02013;35.1)</td><td align="center" rowspan="1" colspan="1">2.99 (0.02&#x02013;99.4)</td><td align="center" rowspan="1" colspan="1">2.60 (0&#x02013;70.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>4</sub> (mg/mmol)</td><td align="center" rowspan="1" colspan="1">0.21 (0&#x02013;3.94)</td><td align="center" rowspan="1" colspan="1">1.02 (0.04&#x02013;7.16)</td><td align="center" rowspan="1" colspan="1">0.50 (0.03&#x02013;28.7)</td><td align="center" rowspan="1" colspan="1">0.15 (0&#x02013;53.7) <break/> (<italic>n</italic> = 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgG<sub>2</sub>/u-IgG<sub>4 </sub>
</td><td align="center" rowspan="1" colspan="1">1.88 (1&#x02013;10.5)</td><td align="center" rowspan="1" colspan="1">3.05 (0.33&#x02013;9.16)</td><td align="center" rowspan="1" colspan="1">5.57 (0.8&#x02013;9.7)</td><td align="center" rowspan="1" colspan="1">4.47 (0.35&#x02013;24.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-GAG (mg/mmol)</td><td align="center" rowspan="1" colspan="1">2.31 (0&#x02013;4.52)</td><td align="center" rowspan="1" colspan="1">3.97 (1.25&#x02013;6.1)<sup>&#x02217;##</sup>
</td><td align="center" rowspan="1" colspan="1">2.70 (0&#x02013;11.1)</td><td align="center" rowspan="1" colspan="1">2.49 (0&#x02013;5.19) <break/> (<italic>n</italic> = 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">U-IgM (mg/mmol)</td><td align="center" rowspan="1" colspan="1">0.03 (0&#x02013;0.05)</td><td align="center" rowspan="1" colspan="1">0.03 (0.01&#x02013;0.12)</td><td align="center" rowspan="1" colspan="1">0.03 (0&#x02013;0.13)</td><td align="center" rowspan="1" colspan="1">0.02 (0&#x02013;0.14)</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-<italic>&#x003b2;</italic>1 (mg/mmol)</td><td align="center" rowspan="1" colspan="1">4.44 (1.4&#x02013;15.9)</td><td align="center" rowspan="1" colspan="1">4.09 (2.14&#x02013;14.12)</td><td align="center" rowspan="1" colspan="1">4.5 (1.8&#x02013;16.5)</td><td align="center" rowspan="1" colspan="1">3.5 (1.19&#x02013;22.44) <break/>(<italic>n</italic> = 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">GFR (mL/min)</td><td align="center" rowspan="1" colspan="1">74 (36&#x02013;140) <break/>(<italic>n</italic> = 8)</td><td align="center" rowspan="1" colspan="1">76 (18&#x02013;208) <break/> (<italic>n</italic> = 9)</td><td align="center" rowspan="1" colspan="1">71 (38&#x02013;107) <break/> (<italic>n</italic> = 10)</td><td align="center" rowspan="1" colspan="1">67 (34&#x02013;113) <break/> (<italic>n</italic> = 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">IGFBP-1 (<italic>&#x003bc;</italic>g/L)</td><td align="center" rowspan="1" colspan="1">66 (8&#x02013;313)</td><td align="center" rowspan="1" colspan="1">105 (23&#x02013;219)*<break/> (<italic>n</italic> = 9)</td><td align="center" rowspan="1" colspan="1">60 (20&#x02013;130)</td><td align="center" rowspan="1" colspan="1">46 (10&#x02013;161)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are given as the median (with minimum and maximum values in parentheses) of the ratio between urinary concentrations of substance and u-creatinine. *<italic>P</italic> &#x0003c; 0.05 versus placebo; <sup>##</sup>
<italic>P</italic> &#x0003c; 0.01 versus baseline. GFR: glomerular filtration rate: creatinine clearance.</p></fn></table-wrap-foot></table-wrap></floats-group></article>